This site is intended for health professionals only
Monday 21 May 2012
Facebook Twiter Linkedin

What, if not antipsychotics?

19 Oct 2010

The DH insists an antipsychotic prescription isn’t ‘quality care’ for dementia, but cops out of suggesting alternatives, says Copperfield

Forgotten password?
The page you are looking for is only available to logged in members of PulseToday.
Not a member yet?
Register now for free
If you are not a registered user, then please sign up here. Registering is totally free and takes just seconds. It gives you access to up-to-the minute news alerts and analysis, all our top bloggers (including Copperfield and Peverley) and our education content, including clinical articles, videos and downloads.
If you experience any difficulties logging in or registering, or have any other questions, please contact PulseToday at feedback@pulsetoday.co.uk or 020 7921 8091.

READERS' COMMENTS

Anonymous,
20 Oct 2010
Hurray for Copperfield! I have been having this same rant every time the story of unnecessary use of antipsychotics appears on the news. As we all know, every drug comes with side-effects and risks, and it's always a balance as to whether the benefits outweigh those risks. Pamela Manners
Average (0Votes)
Top
Anonymous,
20 Oct 2010
Well said Lobley !!! This is nothing more than an attempt to save money yet social care budgets are being reduced, surely Rx levels will go up Tim Southwood
Average (0Votes)
Top
Anonymous,
21 Oct 2010
This is an evocative issue. We cannot ignore objective evidence showing lack of benefit of antipsychotics for many behavioural problems in dementia unless the patient is heavily sedated. Patients often cannot consent to the intervention. The Banerjee report suggests 20% are likely to benefit and the additional mortality is 1800 per year. Risperidone is licensed for short term usage for management of aggression/agitation though. Part of the problem may be, as alluded to by Copperfield, that use of the drugs for dementia, particularly memantine (severe disease), have not been supported by NICE. NICE now acknowledge that acetylcholinesterase inhibitors and memantine can affect behavioural symptoms. This is true for apathy, anxiety and dysphoria for acetylcholinesterase inhibitors and for agitation, aggression and irritability for memantine. I find in clinical practice this is definitely the case. We always look for precipitants of behavioural symptoms eg pain, infection, delirium. Antipsychotic use may be inevitable but I find this is mitigated by proper assessment and use of the therapeutic approaches now recommended by NICE in mild, moderate and severe dementia. This might actually incur more expense. The need for good quality care in dementia is a point well made

peter passmore
Average (0Votes)
Top
Anonymous, Other healthcare professional,
03 Nov 2011
Anonymous, 20 Oct 2010
Well said Lobley !!! This is nothing more than an attempt to save money yet social care budgets are being reduced, surely Rx levels will go up Tim Southwood

Hmm, and the extra staffing (maybe desirable) will mean nursing home costs will rise ......
Average (0Votes)
Top

ADD YOUR COMMENTS

Please note You must be a registered user of PulseToday and logged in to add comments. Opinions expressed below are those of the writers and do not necessarily reflect those of PulseToday. Comments are considered in the public domain and may be used in future Pulse coverage. We accept no responsibility, legal or otherwise, for the accuracy or the content of member comments.

Comment*

You must be logged in to add a comment.Clickhere to login.

POLL

Are GPs ordering too many lab tests?Read the full story here

SIGN UP FOR EMAIL NEWSLETTERS

Keep up-to-date with the latest changes to the NHS, CPD and clinical guidelines. Sign up below or find out more.